Treatment Study for Ischemic Optic Neuropathy With Opthalmic Timolol Maleate 0.5%
Status:
Withdrawn
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the feasibility of rapid evaluation and
administration of ophthalmic Timolol maleate in the treatment of non-arteritic anterior
ischemic optic neuropathy. Secondary goals are to evaluate if such treatment reduces the
progression or improves recovery of patients who are randomly assigned to treatment versus
standard of care.